Compile Data Set for Download or QSAR
Found 108 Enz. Inhib. hit(s) with all data for entry = 2333
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19515((2R)-N-(1-cyanocyclopropyl)-3-[(3,4-dichlorobenzen...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C21H17Cl2F4N3O3S/c22-15-6-5-14(9-16(15)23)34(32,33)10-17(19(31)30-20(11-28)7-8-20)29-18(21(25,26)27)12-1-3-13(24)4-2-12/h1-6,9,17-18,29H,7-8,10H2,(H,30,31)/t17-,18-/m0/s1
Affinity DataIC50: 0.200nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19514((2R)-N-(1-cyanocyclopropyl)-3-[(3,4-dichlorobenzen...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H18Cl2F3N3O3S/c22-15-7-6-14(10-16(15)23)33(31,32)11-17(19(30)29-20(12-27)8-9-20)28-18(21(24,25)26)13-4-2-1-3-5-13/h1-7,10,17-18,28H,8-9,11H2,(H,29,30)/t17-,18-/m0/s1
Affinity DataIC50: 0.200nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19489((2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifl...)
Show SMILES CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NCC#N
Show InChI InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
Affinity DataIC50: 0.200nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19511((2R)-3-[(3-bromobenzene)sulfonyl]-N-(1-cyanocyclop...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1cccc(Br)c1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H19BrF3N3O3S/c22-15-7-4-8-16(11-15)32(30,31)12-17(19(29)28-20(13-26)9-10-20)27-18(21(23,24)25)14-5-2-1-3-6-14/h1-8,11,17-18,27H,9-10,12H2,(H,28,29)/t17-,18-/m0/s1
Affinity DataIC50: 0.200nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19491((2S)-N-(1-cyanocyclopropyl)-4-methyl-2-{[(1S)-2,2,...)
Show SMILES CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C25H28F3N3O3S/c1-16(2)14-21(23(32)31-24(15-29)12-13-24)30-22(25(26,27)28)19-6-4-17(5-7-19)18-8-10-20(11-9-18)35(3,33)34/h4-11,16,21-22,30H,12-14H2,1-3H3,(H,31,32)/t21-,22-/m0/s1
Affinity DataIC50: 0.300nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19510((2R)-3-[(4-bromobenzene)sulfonyl]-N-(1-cyanocyclop...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1ccc(Br)cc1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H19BrF3N3O3S/c22-15-6-8-16(9-7-15)32(30,31)12-17(19(29)28-20(13-26)10-11-20)27-18(21(23,24)25)14-4-2-1-3-5-14/h1-9,17-18,27H,10-12H2,(H,28,29)/t17-,18-/m0/s1
Affinity DataIC50: 0.300nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19505((2R)-N-(1-cyanocyclopropyl)-3-{[(2,3-difluoropheny...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)Cc1cccc(F)c1F)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C22H19F6N3O3S/c23-15-6-4-13(5-7-15)19(22(26,27)28)30-17(20(32)31-21(12-29)8-9-21)11-35(33,34)10-14-2-1-3-16(24)18(14)25/h1-7,17,19,30H,8-11H2,(H,31,32)/t17-,19-/m0/s1
Affinity DataIC50: 0.300nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19504((2R)-N-(1-cyanocyclopropyl)-3-{[(2,3-difluoropheny...)
Show SMILES Fc1cccc(CS(=O)(=O)C[C@H](N[C@@H](c2ccccc2)C(F)(F)F)C(=O)NC2(CC2)C#N)c1F
Show InChI InChI=1S/C22H20F5N3O3S/c23-16-8-4-7-15(18(16)24)11-34(32,33)12-17(20(31)30-21(13-28)9-10-21)29-19(22(25,26)27)14-5-2-1-3-6-14/h1-8,17,19,29H,9-12H2,(H,30,31)/t17-,19-/m0/s1
Affinity DataIC50: 0.300nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19500((2R)-N-(1-cyanocyclopropyl)-3-[(2-methylpropane)su...)
Show SMILES CC(C)CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C19H23F4N3O3S/c1-12(2)9-30(28,29)10-15(17(27)26-18(11-24)7-8-18)25-16(19(21,22)23)13-3-5-14(20)6-4-13/h3-6,12,15-16,25H,7-10H2,1-2H3,(H,26,27)/t15-,16-/m0/s1
Affinity DataIC50: 0.400nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19509((2R)-N-(1-cyanocyclopropyl)-3-[(4-fluorobenzene)su...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)c1ccc(F)cc1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C21H18F5N3O3S/c22-14-3-1-13(2-4-14)18(21(24,25)26)28-17(19(30)29-20(12-27)9-10-20)11-33(31,32)16-7-5-15(23)6-8-16/h1-8,17-18,28H,9-11H2,(H,29,30)/t17-,18-/m0/s1
Affinity DataIC50: 0.400nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19503((2R)-N-(1-cyanocyclopropyl)-3-{[(4-fluorophenyl)me...)
Show SMILES Fc1ccc(CS(=O)(=O)C[C@H](N[C@@H](c2ccccc2)C(F)(F)F)C(=O)NC2(CC2)C#N)cc1
Show InChI InChI=1S/C22H21F4N3O3S/c23-17-8-6-15(7-9-17)12-33(31,32)13-18(20(30)29-21(14-27)10-11-21)28-19(22(24,25)26)16-4-2-1-3-5-16/h1-9,18-19,28H,10-13H2,(H,29,30)/t18-,19-/m0/s1
Affinity DataIC50: 0.5nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19502((2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethane)...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)CC1CC1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C19H21F4N3O3S/c20-14-5-3-13(4-6-14)16(19(21,22)23)25-15(10-30(28,29)9-12-1-2-12)17(27)26-18(11-24)7-8-18/h3-6,12,15-16,25H,1-2,7-10H2,(H,26,27)/t15-,16-/m0/s1
Affinity DataIC50: 0.5nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19501((2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethane)...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)CC1CC1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C19H22F3N3O3S/c20-19(21,22)16(14-4-2-1-3-5-14)24-15(11-29(27,28)10-13-6-7-13)17(26)25-18(12-23)8-9-18/h1-5,13,15-16,24H,6-11H2,(H,25,26)/t15-,16-/m0/s1
Affinity DataIC50: 0.600nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19506((2R)-N-(1-cyanocyclopropyl)-3-{[(2,6-dichloropheny...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)Cc1c(Cl)cccc1Cl)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C22H19Cl2F4N3O3S/c23-16-2-1-3-17(24)15(16)10-35(33,34)11-18(20(32)31-21(12-29)8-9-21)30-19(22(26,27)28)13-4-6-14(25)7-5-13/h1-7,18-19,30H,8-11H2,(H,31,32)/t18-,19-/m0/s1
Affinity DataIC50: 0.700nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19516((2S)-N-[(3S,5E)-6-(benzenesulfonyl)-4-oxo-1-phenyl...)
Show SMILES CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@H](CCc1ccccc1)C=CS(=O)(=O)c1ccccc1
Show InChI InChI=1S/C28H37N3O5S/c1-22(2)21-26(30-28(33)31-16-18-36-19-17-31)27(32)29-24(14-13-23-9-5-3-6-10-23)15-20-37(34,35)25-11-7-4-8-12-25/h3-12,15,20,22,24,26H,13-14,16-19,21H2,1-2H3,(H,29,32)(H,30,33)/t24-,26-/m1/s1
Affinity DataIC50: 1.20nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19513((2R)-3-(1,3-benzothiazole-2-sulfonyl)-N-(1-cyanocy...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1nc2ccccc2s1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C22H19F3N4O3S2/c23-22(24,25)18(14-6-2-1-3-7-14)27-16(19(30)29-21(13-26)10-11-21)12-34(31,32)20-28-15-8-4-5-9-17(15)33-20/h1-9,16,18,27H,10-12H2,(H,29,30)/t16-,18-/m0/s1
Affinity DataIC50: 1.30nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19507((2R)-N-(1-cyanocyclopropyl)-3-{[(2-phenylphenyl)me...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)Cc1ccccc1-c1ccccc1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C28H25F4N3O3S/c29-22-12-10-20(11-13-22)25(28(30,31)32)34-24(26(36)35-27(18-33)14-15-27)17-39(37,38)16-21-8-4-5-9-23(21)19-6-2-1-3-7-19/h1-13,24-25,34H,14-17H2,(H,35,36)/t24-,25-/m0/s1
Affinity DataIC50: 1.80nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19496((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17F4N3O3S/c1-27(25,26)8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 1.80nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19499((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccccc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H18F3N3O3S/c1-26(24,25)9-12(14(23)22-15(10-20)7-8-15)21-13(16(17,18)19)11-5-3-2-4-6-11/h2-6,12-13,21H,7-9H2,1H3,(H,22,23)/t12-,13-/m0/s1
Affinity DataIC50: 2.5nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19493((2R)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroeth...)
Show SMILES CSC[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17BrF3N3OS/c1-25-8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 5nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19512((2R)-N-(1-cyanocyclopropyl)-3-(1,3-thiazole-2-sulf...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1nccs1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C18H17F3N4O3S2/c19-18(20,21)14(12-4-2-1-3-5-12)24-13(15(26)25-17(11-22)6-7-17)10-30(27,28)16-23-8-9-29-16/h1-5,8-9,13-14,24H,6-7,10H2,(H,25,26)/t13-,14-/m0/s1
Affinity DataIC50: 5nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19495((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C22H21F4N3O3S/c1-33(31,32)12-18(20(30)29-21(13-27)10-11-21)28-19(22(24,25)26)16-4-2-14(3-5-16)15-6-8-17(23)9-7-15/h2-9,18-19,28H,10-12H2,1H3,(H,29,30)/t18-,19-/m0/s1
Affinity DataIC50: 5.30nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19516((2S)-N-[(3S,5E)-6-(benzenesulfonyl)-4-oxo-1-phenyl...)
Show SMILES CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@H](CCc1ccccc1)C=CS(=O)(=O)c1ccccc1
Show InChI InChI=1S/C28H37N3O5S/c1-22(2)21-26(30-28(33)31-16-18-36-19-17-31)27(32)29-24(14-13-23-9-5-3-6-10-23)15-20-37(34,35)25-11-7-4-8-12-25/h3-12,15,20,22,24,26H,13-14,16-19,21H2,1-2H3,(H,29,32)(H,30,33)/t24-,26-/m1/s1
Affinity DataIC50: 5.70nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19516((2S)-N-[(3S,5E)-6-(benzenesulfonyl)-4-oxo-1-phenyl...)
Show SMILES CC(C)C[C@@H](NC(=O)N1CCOCC1)C(=O)N[C@H](CCc1ccccc1)C=CS(=O)(=O)c1ccccc1
Show InChI InChI=1S/C28H37N3O5S/c1-22(2)21-26(30-28(33)31-16-18-36-19-17-31)27(32)29-24(14-13-23-9-5-3-6-10-23)15-20-37(34,35)25-11-7-4-8-12-25/h3-12,15,20,22,24,26H,13-14,16-19,21H2,1-2H3,(H,29,32)(H,30,33)/t24-,26-/m1/s1
Affinity DataIC50: 6.20nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19498((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1cccc(F)c1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17F4N3O3S/c1-27(25,26)8-12(14(24)23-15(9-21)5-6-15)22-13(16(18,19)20)10-3-2-4-11(17)7-10/h2-4,7,12-13,22H,5-6,8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 6.40nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19495((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C22H21F4N3O3S/c1-33(31,32)12-18(20(30)29-21(13-27)10-11-21)28-19(22(24,25)26)16-4-2-14(3-5-16)15-6-8-17(23)9-7-15/h2-9,18-19,28H,10-12H2,1H3,(H,29,30)/t18-,19-/m0/s1
Affinity DataIC50: 10nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19492((2R)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroeth...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17BrF3N3O3S/c1-27(25,26)8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 11nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19510((2R)-3-[(4-bromobenzene)sulfonyl]-N-(1-cyanocyclop...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1ccc(Br)cc1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H19BrF3N3O3S/c22-15-6-8-16(9-7-15)32(30,31)12-17(19(29)28-20(13-26)10-11-20)27-18(21(23,24)25)14-4-2-1-3-5-14/h1-9,17-18,27H,10-12H2,(H,28,29)/t17-,18-/m0/s1
Affinity DataIC50: 15nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19509((2R)-N-(1-cyanocyclopropyl)-3-[(4-fluorobenzene)su...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)c1ccc(F)cc1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C21H18F5N3O3S/c22-14-3-1-13(2-4-14)18(21(24,25)26)28-17(19(30)29-20(12-27)9-10-20)11-33(31,32)16-7-5-15(23)6-8-16/h1-8,17-18,28H,9-11H2,(H,29,30)/t17-,18-/m0/s1
Affinity DataIC50: 22nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19511((2R)-3-[(3-bromobenzene)sulfonyl]-N-(1-cyanocyclop...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1cccc(Br)c1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H19BrF3N3O3S/c22-15-7-4-8-16(11-15)32(30,31)12-17(19(29)28-20(13-26)9-10-20)27-18(21(23,24)25)14-5-2-1-3-6-14/h1-8,11,17-18,27H,9-10,12H2,(H,28,29)/t17-,18-/m0/s1
Affinity DataIC50: 23nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19514((2R)-N-(1-cyanocyclopropyl)-3-[(3,4-dichlorobenzen...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H18Cl2F3N3O3S/c22-15-7-6-14(10-16(15)23)33(31,32)11-17(19(30)29-20(12-27)8-9-20)28-18(21(24,25)26)13-4-2-1-3-5-13/h1-7,10,17-18,28H,8-9,11H2,(H,29,30)/t17-,18-/m0/s1
Affinity DataIC50: 24nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19492((2R)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroeth...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17BrF3N3O3S/c1-27(25,26)8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 31nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19515((2R)-N-(1-cyanocyclopropyl)-3-[(3,4-dichlorobenzen...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)c1ccc(Cl)c(Cl)c1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C21H17Cl2F4N3O3S/c22-15-6-5-14(9-16(15)23)34(32,33)10-17(19(31)30-20(11-28)7-8-20)29-18(21(25,26)27)12-1-3-13(24)4-2-12/h1-6,9,17-18,29H,7-8,10H2,(H,30,31)/t17-,18-/m0/s1
Affinity DataIC50: 41nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19501((2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethane)...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)CC1CC1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C19H22F3N3O3S/c20-19(21,22)16(14-4-2-1-3-5-14)24-15(11-29(27,28)10-13-6-7-13)17(26)25-18(12-23)8-9-18/h1-5,13,15-16,24H,6-11H2,(H,25,26)/t15-,16-/m0/s1
Affinity DataIC50: 68nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19493((2R)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroeth...)
Show SMILES CSC[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17BrF3N3OS/c1-25-8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 80nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19503((2R)-N-(1-cyanocyclopropyl)-3-{[(4-fluorophenyl)me...)
Show SMILES Fc1ccc(CS(=O)(=O)C[C@H](N[C@@H](c2ccccc2)C(F)(F)F)C(=O)NC2(CC2)C#N)cc1
Show InChI InChI=1S/C22H21F4N3O3S/c23-17-8-6-15(7-9-17)12-33(31,32)13-18(20(30)29-21(14-27)10-11-21)28-19(22(24,25)26)16-4-2-1-3-5-16/h1-9,18-19,28H,10-13H2,(H,29,30)/t18-,19-/m0/s1
Affinity DataIC50: 86nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19504((2R)-N-(1-cyanocyclopropyl)-3-{[(2,3-difluoropheny...)
Show SMILES Fc1cccc(CS(=O)(=O)C[C@H](N[C@@H](c2ccccc2)C(F)(F)F)C(=O)NC2(CC2)C#N)c1F
Show InChI InChI=1S/C22H20F5N3O3S/c23-16-8-4-7-15(18(16)24)11-34(32,33)12-17(20(31)30-21(13-28)9-10-21)29-19(22(25,26)27)14-5-2-1-3-6-14/h1-8,17,19,29H,9-12H2,(H,30,31)/t17-,19-/m0/s1
Affinity DataIC50: 105nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19513((2R)-3-(1,3-benzothiazole-2-sulfonyl)-N-(1-cyanocy...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1nc2ccccc2s1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C22H19F3N4O3S2/c23-22(24,25)18(14-6-2-1-3-7-14)27-16(19(30)29-21(13-26)10-11-21)12-34(31,32)20-28-15-8-4-5-9-17(15)33-20/h1-9,16,18,27H,10-12H2,(H,29,30)/t16-,18-/m0/s1
Affinity DataIC50: 114nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19505((2R)-N-(1-cyanocyclopropyl)-3-{[(2,3-difluoropheny...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)Cc1cccc(F)c1F)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C22H19F6N3O3S/c23-15-6-4-13(5-7-15)19(22(26,27)28)30-17(20(32)31-21(12-29)8-9-21)11-35(33,34)10-14-2-1-3-16(24)18(14)25/h1-7,17,19,30H,8-11H2,(H,31,32)/t17-,19-/m0/s1
Affinity DataIC50: 121nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19500((2R)-N-(1-cyanocyclopropyl)-3-[(2-methylpropane)su...)
Show SMILES CC(C)CS(=O)(=O)C[C@H](N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C19H23F4N3O3S/c1-12(2)9-30(28,29)10-15(17(27)26-18(11-24)7-8-18)25-16(19(21,22)23)13-3-5-14(20)6-4-13/h3-6,12,15-16,25H,7-10H2,1-2H3,(H,26,27)/t15-,16-/m0/s1
Affinity DataIC50: 132nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19499((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccccc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H18F3N3O3S/c1-26(24,25)9-12(14(23)22-15(10-20)7-8-15)21-13(16(17,18)19)11-5-3-2-4-6-11/h2-6,12-13,21H,7-9H2,1H3,(H,22,23)/t12-,13-/m0/s1
Affinity DataIC50: 141nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin B(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19495((2R)-N-(1-cyanocyclopropyl)-3-methanesulfonyl-2-{[...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(F)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C22H21F4N3O3S/c1-33(31,32)12-18(20(30)29-21(13-27)10-11-21)28-19(22(24,25)26)16-4-2-14(3-5-16)15-6-8-17(23)9-7-15/h2-9,18-19,28H,10-12H2,1H3,(H,29,30)/t18-,19-/m0/s1
Affinity DataIC50: 170nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19489((2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifl...)
Show SMILES CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NCC#N
Show InChI InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
Affinity DataIC50: 178nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19512((2R)-N-(1-cyanocyclopropyl)-3-(1,3-thiazole-2-sulf...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1nccs1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C18H17F3N4O3S2/c19-18(20,21)14(12-4-2-1-3-5-12)24-13(15(26)25-17(11-22)6-7-17)10-30(27,28)16-23-8-9-29-16/h1-5,8-9,13-14,24H,6-7,10H2,(H,25,26)/t13-,14-/m0/s1
Affinity DataIC50: 181nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19502((2R)-N-(1-cyanocyclopropyl)-3-(cyclopropylmethane)...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)CC1CC1)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C19H21F4N3O3S/c20-14-5-3-13(4-6-14)16(19(21,22)23)25-15(10-30(28,29)9-12-1-2-12)17(27)26-18(11-24)7-8-18/h3-6,12,15-16,25H,1-2,7-10H2,(H,26,27)/t15-,16-/m0/s1
Affinity DataIC50: 188nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19506((2R)-N-(1-cyanocyclopropyl)-3-{[(2,6-dichloropheny...)
Show SMILES Fc1ccc(cc1)[C@H](N[C@@H](CS(=O)(=O)Cc1c(Cl)cccc1Cl)C(=O)NC1(CC1)C#N)C(F)(F)F
Show InChI InChI=1S/C22H19Cl2F4N3O3S/c23-16-2-1-3-17(24)15(16)10-35(33,34)11-18(20(32)31-21(12-29)8-9-21)30-19(22(26,27)28)13-4-6-14(25)7-5-13/h1-7,18-19,30H,8-11H2,(H,31,32)/t18-,19-/m0/s1
Affinity DataIC50: 249nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetProcathepsin L(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19489((2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifl...)
Show SMILES CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NCC#N
Show InChI InChI=1S/C23H26F3N3O3S/c1-15(2)14-20(22(30)28-13-12-27)29-21(23(24,25)26)18-6-4-16(5-7-18)17-8-10-19(11-9-17)33(3,31)32/h4-11,15,20-21,29H,13-14H2,1-3H3,(H,28,30)/t20-,21-/m0/s1
Affinity DataIC50: 264nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin S(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19491((2S)-N-(1-cyanocyclopropyl)-4-methyl-2-{[(1S)-2,2,...)
Show SMILES CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C25H28F3N3O3S/c1-16(2)14-21(23(32)31-24(15-29)12-13-24)30-22(25(26,27)28)19-6-4-17(5-7-19)18-8-10-20(11-9-18)35(3,33)34/h4-11,16,21-22,30H,12-14H2,1-3H3,(H,31,32)/t21-,22-/m0/s1
Affinity DataIC50: 265nMpH: 6.5 T: 2°CAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin K(Oryctolagus cuniculus (rabbit))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19511((2R)-3-[(3-bromobenzene)sulfonyl]-N-(1-cyanocyclop...)
Show SMILES FC(F)(F)[C@@H](N[C@@H](CS(=O)(=O)c1cccc(Br)c1)C(=O)NC1(CC1)C#N)c1ccccc1
Show InChI InChI=1S/C21H19BrF3N3O3S/c22-15-7-4-8-16(11-15)32(30,31)12-17(19(29)28-20(13-26)9-10-20)27-18(21(23,24)25)14-5-2-1-3-6-14/h1-8,11,17-18,27H,9-10,12H2,(H,28,29)/t17-,18-/m0/s1
Affinity DataIC50: 269nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
TargetCathepsin B(Homo sapiens (Human))
Merck Frosst Centre for Therapeutic Research

LigandPNGBDBM19492((2R)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroeth...)
Show SMILES CS(=O)(=O)C[C@H](N[C@@H](c1ccc(Br)cc1)C(F)(F)F)C(=O)NC1(CC1)C#N
Show InChI InChI=1S/C16H17BrF3N3O3S/c1-27(25,26)8-12(14(24)23-15(9-21)6-7-15)22-13(16(18,19)20)10-2-4-11(17)5-3-10/h2-5,12-13,22H,6-8H2,1H3,(H,23,24)/t12-,13-/m0/s1
Affinity DataIC50: 282nMAssay Description:Prior to the addition of substrate, different concentrations of the inhibitor ranging from 100 uM to 0.2 nM were preincubated for 15 min with enzyme ...More data for this Ligand-Target Pair
Displayed 1 to 50 (of 108 total ) | Next | Last >>
Jump to: